Global Medical Device Podcast powered by Greenlight Guru

Building a medical device rarely follows the smooth, predictable trajectory presented in investor pitch decks. While regulatory consultants often default to "it depends," medical device teams require concrete figures regarding engineering hours, calendar timelines, and budget allocations to bring a concept to market safely and effectively. Lisa Voronkova, co-founder of OVA Solutions, draws on a dataset from developing over 200 medical devices to pull back the curtain on hardware engineering realities. She outlines the four structured phases of engineering—Discovery, Proof of Concept, Design, and Development—explaining how disciplined phase-gate management mitigates costly late-stage redesigns and protects capital. The conversation dives into transparent, real-world case studies ranging from short pre-production hardware tracks to complex, multi-year continuous glucose monitor (CGM) developments. Lisa and host Etienne Nichols explore the true financial scope of Design for Manufacturability (DFM), realistic blended hourly rates across global markets, and why shortcuts in early contextual validation often lead to catastrophic manufacturing overhead. Takeaways Phase-Gate Discipline Controls Financial Risk: Moving into high-cost tooling or manufacturing before proving core function in a low-fidelity mock-up risks turning a $1,500 prototype adjustment into a $150,000 production mold tool rework. Validate in the Real Operating Environment: Conducting customer interviews is insufficient if engineers do not observe the actual clinical setting; lighting conditions, sterile field constraints, and physical workflows dictate foundational hardware requirements. Benchmark Engineering Hours accurately: Standard hardware projects generally fall into three tiers: 2,000–3,000 hours for simple electronics integrations, 5,000–6,000 hours for multi-system electro-mechanical devices, and 10,000–30,000+ hours for high-complexity Class II/III systems (e.g., CGMs, surgical robotics). DFM Accounts for a Massive Secondary Investment: Completing the initial "golden sample" prototype is only half the engineering journey; preparing a device for mass production (assembly sequences, test fixtures, second-sourcing components) can demand an additional 2,500 to 7,000+ engineering hours. References OVA Solutions: Engineering group specializing in full-cycle medical device design, electronics, and firmware development. The Hardware Bible: Book authored by Lisa Voronkova detailing practical expectations and framework strategies for medical device development. Host LinkedIn: Connect with Etienne Nichols on LinkedIn for ongoing discussions with MedTech industry leaders. Feedback Call-to-Action We want to hear from you! What was your biggest takeaway regarding medical device engineering budgets and timelines? Have a guest recommendation or a topic you want us to dissect in an upcoming episode? Send your feedback, reviews, and topic suggestions directly to [email protected]. Etienne reads every message and responds personally to our listeners! Sponsors This episode is brought to you by Greenlight Guru. Learn more at www.greenlight.guru.

In this episode of the Global Medical Device Podcast, host Etienne Nichols sits down with Nikhil Mangale, Vice President of Quality at Kapstone Medical, to discuss the real-world impact of the FDA's Quality Management System Regulation (QMSR). Seven months post-implementation, the industry is seeing actual inspection data that shifts the focus away from superficial documentation updates and directly onto core quality system operations. Nikhil breaks down the top five areas where the FDA is issuing citations under the new regulation: risk management, supplier controls, complaint handling, Unique Device Identification (UDI), and corrective actions. The discussion highlights how the industry spent years worrying about renaming documents like Design History Files (DHFs) to Design and Development Files (DDFs), yet inspectors are bypassing mere translation projects to evaluate how information flows across living quality processes. The conversation offers actionable guidance on conducting thorough, multi-layered gap assessments for both active and legacy products. Nikhil provides strategic advice for small companies and startups on prioritizing risk management, handling supplier audit visibility, navigating ISO 13485 alignment, and weighing the benefits of participating in programs like MDSAP. Takeaways Prioritize Risk as a Living Process: Risk management must continuously integrate post-market feedback, complaint data, and nonconformances rather than remaining a static file archived after design release. Re-evaluate Supplier Audits for External Scrutiny: Routine supplier audit records are now accessible to FDA inspectors; ensure reports are well-documented, audit schedules are risk-proportionate, and findings are formally resolved. Implement a Three-Layer Mapping Strategy: Move beyond surface-level terminology updates (Layer 1) to establish subclause conformity (Layer 2) and verify operational evidence across interrelated processes (Layer 3). Maintain Open Design and Development Files (DDF): Unlike legacy DHFs that were closed at commercial launch, DDFs must remain active throughout the product lifecycle to evaluate ongoing design changes. Formulate a Defensible Quality Plan: When addressing gaps, document a risk-prioritized, sequential quality plan to show objective evidence of a structured compliance roadmap during an inspection. References FDA Compliance Program CP 7382.045: The FDA inspection guidance replacing QSIT, organizing surveillance around core QMS areas and specific regulations. ISO 13485:2016: The international standard for medical device quality management systems incorporated by reference into the FDA's QMSR. Etienne Nichols LinkedIn Profile - Connect with the host of the Global Medical Device Podcast. Feedback Call-to-Action We want to hear from you! What challenges are you experiencing with your QMSR implementation or risk management files? Send your feedback, reviews, or topic suggestions directly to [email protected]. We personally review and respond to every message from our listeners! Sponsors This episode is brought to you by Greenlight Guru.

The transition from academic research to commercial MedTech entrepreneurship requires a strategic mindset shift, particularly when navigating high-risk vascular innovations. Jordi Martorell, CEO and co-founder of Aortyx, shares his journey from mapping arterial blood flow at the Harvard-MIT Biomedical Engineering Center to developing bioresorbable endovascular patches for aortic dissection. Driven by a desire to solve true unmet medical needs, Martorell leveraged his background in fluid mechanics and vascular engineering to build a company capable of transforming clinical outcomes. Navigating early-stage funding outside major venture capital hubs presents unique structural challenges. Martorell explains how Aortyx sustained a multi-year development timeline prior to Series A by combining friends-and-family rounds, community equity crowdfunding, and non-dilutive European public grants. Maintaining radical transparency regarding investment risk and establishing clean cap table structures were critical components in maintaining investor trust over extended timelines. Securing a Series A round for a Class III medical device requires managing shifting macroeconomic landscapes, rising clinical costs, and complex regulatory pathways. Martorell reflects on the realities of negotiating with venture capital firms, facing unexpected round restructurings, and adapting to post-pandemic inflation across preclinical and clinical trial execution. The discussion highlights the importance of maintaining core product continuity while remaining flexible in execution strategy. Takeaways Validate Unmet Needs Over Market Incrementalism: Avoid competing in saturated markets where large strategics only seek non-inferiority; focus R&D on clear, unaddressed clinical gaps. Structure Clean Cap Tables for Retail Capital: When utilizing equity crowdfunding or large groups of early individual investors, leverage syndication and SPVs to preserve a single point of negotiation for future institutional VCs. Prepare for Extended Series A Timelines: Deep-tech Class III devices can face multi-year fundraising cycles, requiring a multi-tiered capital strategy blending non-dilutive grants, bridge rounds, and follow-on commitments. Factor Post-Pandemic Inflation into Preclinical Budgets: Account for significant cost increases in animal studies, raw material procurement, and clinical trial execution compared to historical baseline estimates. References Aortyx: Medical device company developing bioresorbable endovascular patches for aortic dissection repair. EIC Accelerator Program: European Innovation Council grant initiative providing non-dilutive funding to high-impact European startups. Capital Cell: Specialized health-focused equity crowdfunding platform based in Spain. Etienne Nichols: LinkedIn Profile Feedback Call-to-Action We want to hear from you. What were your key takeaways from this episode? Do you have topics or guest suggestions for future discussions? Send your thoughts, feedback, and questions directly to [email protected]. Every email is reviewed by our team to help shape upcoming episodes. Sponsors This episode is brought to you by Greenlight Guru. Learn how Greenlight Guru's modern QMS and EDC software can support your medical device journey at greenlight.guru.

Medical device cybersecurity is no longer an optional feature or a last-minute checkbox prior to market entry. Hosted by Etienne Nichols, this episode features Chris Gates, founder and CEO of arsMedSecurity, who delivers a practical, engineering-first perspective on embedding security directly into the development lifecycle. Gates highlights that deferring cybersecurity efforts until the end of development leads to severe financial penalties, extended regulatory delays, and potential company failure. The discussion demystifies common misconceptions held by executive teams and "bean counters," such as the myth that off-network devices or small companies are exempt from cyber threats. Under current FDA expectations and the eStar submission process, any medical device containing software is subject to stringent pre-market cybersecurity requirements. Gates illustrates how unexpected 180-day regulatory holds impact a company's daily burn rate, showing that proactive security measures are far cheaper than reactive fixes. Looking ahead, the conversation explores the evolving threat landscape driven by Large Language Models (LLMs) and advanced exploits that reduce vulnerability exploitation windows from years to minutes. Gates provides concrete steps for medical device manufacturers to take control of their product security, emphasizing early threat modeling, continuous risk management, and the alignment of software development SOPs with recognized international standards. Takeaways Calculate Delay Impact via Burn Rate: Evaluate cybersecurity risk against your organization's daily burn rate multiplied by a potential 180-day FDA submission delay to understand the true financial cost of non-compliance. Software Triggers Cyber Requirements: Do not assume a device is exempt from cybersecurity requirements because it lacks active internet connectivity; any device running software falls under FDA pre-market expectations. Perform Threat Modeling Before Hardware Freeze: Execute system-level threat modeling (e.g., STRIDE methodology) during the initial design phase before finalizing active hardware components and component selections. Adopt Recognized SDLC Standards: Establish standard operating procedures (SOPs) that map secure development activities directly to ISO/IEC 81001-5-1 and ISO 62304 frameworks. References Medical Device Cybersecurity for Engineers and Manufacturers (2nd Edition): Practical reference handbook authored by Chris Gates detailing implementation techniques for device developers. ISO/IEC 81001-5-1: Health software and health IT systems safety, effectiveness, and security standard for secure development lifecycles. STRIDE Threat Model: A system decomposition methodology developed by Microsoft to identify data-in-motion and data-at-rest security threats per system element. Host LinkedIn Profile: Connect with Etienne Nichols on LinkedIn. Feedback Call-to-Action We want to hear from you! What cybersecurity challenges is your team currently navigating during product development? Send your questions, feedback, or topic suggestions directly to us at [email protected]. Every email is reviewed by our team, and we regularly incorporate listener-submitted questions into upcoming episodes and expert Q&A segments. Sponsors This episode is brought to you by Greenlight Guru.

Many MedTech startups and innovators focus heavily on core technology development, often assuming physical product design is simple polishing once a working concept exists. Michael Sprauve explains that this approach frequently creates a gap between brilliant engineering and a market-ready, commercially viable medical device. Succeeding in hardware requires looking past the technology to consider every individual who will interact with the device throughout its entire lifecycle. A critical challenge in MedTech design is managing the complex web of user personas involved. Unlike consumer electronics, where design caters to one or two primary end users, medical devices must meet the needs of surgeons, operating room staff, post-surgical nurses, maintenance technicians, disposal personnel, and regulatory bodies. Overlooking support staff—such as nurses managing crowded, alarm-fatigued rooms or technicians handling biological waste and lithium-ion batteries—can derail an otherwise promising device. As AI image generation tools become widespread, creators increasingly present AI-rendered concepts as finished designs. While these tools offer creative inspiration, they lack awareness of physical constraints, manufacturing rules, and real-world usability. By establishing a non-physical "North Star" based on emotional attributes and sensory cues, design teams can guide products through concepting, engineering, and manufacturing without losing sight of user needs and regulatory mandates. Takeaways Map the Entire User Lifecycle: Design for every individual who touches the product, from the operating surgeon to the maintenance nurse, sterilization technician, and waste handler. Mitigate Alarm Fatigue Early: Ensure auditory and visual indicators comply with FDA standards while avoiding chaotic, high-stress clinical environments caused by competing alerts. Establish a Non-Physical North Star: Use emotional and sensory attributes to anchor design, engineering, and CMF (Color, Material, Finish) choices, keeping the project aligned across development stages. Involve Manufacturing Engineers from Day One: Incorporate Design for Manufacturability (DFM) considerations during initial concept phases rather than waiting until design freeze to prevent expensive re-tooling and regulatory delays. References Speck Design: Hardware design and engineering firm specializing in taking complex medical and life science concepts to market. Intuitive Surgical (DaVinci & Ion Platforms): Advanced robotic-assisted surgical systems highlighting high-precision hardware requirements discussed in the episode. Microport MedBot (Toumai System): Four-arm laparoscopic surgical robot referenced as a key benchmark for international regulatory clearances. Etienne Nichols' LinkedIn: Etienne Nichols on LinkedIn Feedback Call-to-Action We want to hear from you! What challenges have you faced when balancing user feedback against clinical and regulatory requirements? Send your thoughts, topic suggestions, or questions to [email protected]. Every email goes directly to our team, and we personally review listener notes for future episodes. Sponsors This episode is brought to you by Greenlight Guru. Learn more at greenlight.guru.